Table 4.

Median number of drug treatments for the Intention-to-Treat group (Toca FC) and the standard-of-care (SOC) control arm in the Phase 3 trial.

	Toca FC prodrug	Standard of Care (SOC)
		M_TMZ	TMZ	Lomustine	Bevacizumab
Patients	n=197	n=18	n=31	n=66	n=26
Mean Number of Treatment Cycles (SD)	3.4 (3.36)	4.7 (3.80)	4.4 (3.64)	2.3 (1.68)	6.2 (5.49)
Median Number of Treatment Cycles	2	3	3	2	4
Min, Max	1, 21	1, 11	1, 15	1, 7	1, 24

M_TMZ: Temozolomide at a dose of 50 mg/m2 once daily continuously

TMZ: Temozolomide at an initial dose of 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle, that may be raised to 200 mg/m2 once daily for 5 consecutive days in the following 28-day treatment cycles

Lomustine: single oral dose of 110 mg/m2 repeated every 6 weeks

Bevacizumab: 10 mg/kg by intravenous (IV) infusion every 2 weeks; 1 cycle is defined by 2 courses of bevacizumab